Which age group is not recommended to receive the MenB vaccine?

The MenB vaccine, which protects against serogroup B meningococcal disease, is specifically recommended for certain age groups based on risk factors and susceptibility to the disease. The recommendation against administering the MenB vaccine to those under 10 years old aligns with established guidelines that suggest vaccination is primarily for adolescents and younger adults, particularly those aged 16 to 23 years.

Infants can receive the MenB vaccine as early as 2 months of age, while adults who are at increased risk due to specific conditions or environments are also recommended to be vaccinated. Children over 15 years essentially fall into the general adolescent group for whom the vaccine is recommended, especially as they are at higher risk for meningococcal infections. This age-based distinction ensures that vaccination efforts are targeted towards populations most vulnerable to these infections while avoiding unnecessary vaccinations in those who may not benefit from them.